Dynamics of incidence and mortality from Hodgkin's lymphoma in the population of the Amur region (2014–2023)

Aim. To evaluate the territorial features of the main incidence and mortality indicators for malignant lymphomas in the population of the Amur Region from 2014 to 2023. Materials and methods. This study used data from the official oncology service reports (Form 7, “Information on Malignant Neoplasms”) and mortality statistics from local branches of the Federal State Statistics Service, processed using standard oncology statistical software. Results. In the Amur Region in 2023, there were 17.7% more new cases of malignant lymphomas registered compared to 2022. The average statistical incidence rate in 2023 among men was 2.09 ± 0.26 per 100,000 population (p = 0.190) (vs. 1.48 ± 0.25 in 2020), representing a growth rate of +108.4% since 2014. In the female population during the same year, this indicator decreased to 2.08 ± 0.37 per 100,000 (p = 0.918) (vs. 2.34 ± 0.31 in 2020), with a decline rate of –54.3% since 2014. In the structure of classical Hodgkin’s lymphoma forms, nodular sclerosis (70.3%) and mixed cellular lymphoma (23.7%) prevailed. Due to limited capacity of the oncology service in 2020–2023 under the challenging conditions of the COVID19 spread in the studied area, no actively detected cases were registered. The patient accumulation index dropped to 7.2 in 2023 (vs. 10.8 in 2021). The proportion of patients with stage I–II malignancy increased to 19.5% (vs. 12.8% in 2014), as did the share of advanced disease (20.7% vs. 2.9% in 2014). The number of morphological examinations matched the national average (100%). The average mortality rate among men was 0.55±0.07 per 100,000 population (p = 0.352) (vs. 0.51 ± 0.09 in 2020), exceeding that of women, which was 0.42 ± 0.08 (p = 0.317) (vs. 0.93 ± 0.23 in 2020). The number of patients followed for 5 years or more increased to 68.5% (vs. 56.4% in 2014), while the proportion of patients dying within the first year after diagnosis also rose to 29.0% (vs. 27.1% in 2014). Conclusion. The insufficient level of preventive measures did not allow for more extensive active detection of malignant lymphomas between 2014 and 2023 and did not substantially improve the main indicators of medical care for this patient category in the region under study.